FDA releases ICH draft guidance for review "E2D(R1) Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports"
Other than some cut and paste errors in the announcement that left line numbers in it, the clean announcement is below which happens to be the first paragraph from the introduction. This draft guidance is focused on POST-APPROVAL safety reporting, including the terms and their definitions, as well as details for the submission on the specific structure, format, standards, and data elements:
"It is important to establish an internationally standardized procedure to ensure the quality of post-approval safety information and to harmonise, where feasible, the way of gathering and reporting information. The ICH E2D guideline provides guidance on definitions and standards for post-approval individual case safety reporting, as well as good case management practices. This guideline was originally based on the content of the ICH E2A guideline (which provides guidance on pre-approval safety data management), with consideration as to how the terms and definitions should be applied in the post-approval phase of the product life cycle. Detailed guidance on the specific structure, format, standards, and data elements for transmitting Individual Case Safety Reports (ICSRs) is provided in the ICH E2B guideline. Guidance on periodic reporting of aggregated safety data is covered in the ICH E2C guideline."
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2dr1-post-approval-safety-data-definitions-and-standards-management-and-reporting-individual-case
------------------------------
Mark Arnold Ph.D., FAAPS
Westampton, NJ
[email protected]Bioanalytical Solution Integration
LinkedIn:
https://www.linkedin.com/in/markearnoldphd/Website & Blog: Bioanalysis & Biomarkers <bioanalysisandbiomarkers.blogspot.com>
------------------------------
</bioanalysisandbiomarkers.blogspot.com>